Jan 10, 2023 / 05:00PM GMT
Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
Good morning, everyone. Welcome. I'm Robbie Marcus, med tech analyst at JPMorgan. Really happy to introduce our next session with Abbott Labs and the CEO, Robert Ford. Robert, thanks for joining.
Robert B. Ford - Abbott Laboratories - Chairman of the Board, President & CEO
Thanks for having us.
Questions and Answers:
Robert Justin Marcus - JPMorgan Chase & Co, Research Division - AnalystSo I want to start out, 2022 was an interesting year for everyone. Turning the calendar page, we're now in 2023. I thought it would be good to start off with how you see the world, the outlook for Abbott this year.
Robert B. Ford - Abbott Laboratories - Chairman of the Board, President & CEO
Sure. I mean I think you change from one month to the other, one day to the other, it doesn't all go away. I'd say -- I'm not going to give any kind of specific guidance for Abbott today. We'll do that in a